Publications by authors named "C Houillier"
Primary central nervous system lymphoma of the spinal cord: A LOC network cohort study.
Rev Neurol (Paris)
December 2024
Purpose: Primary central nervous system lymphoma (PCNSL) mainly affects the brain (>90% cases); there are very little data pertaining to PCNSL involving the spinal cord.
Methods: We retrospectively selected from the French LOC network database adult immunocompetent patients diagnosed with PCNSL involving the spinal cord between 2011 and 2022.
Results: Of the 2043 patients records retrieved from the database, 16 patients (median age: 62.
Article Synopsis
- Intravascular lymphoma is a rare B-cell lymphoma that primarily affects small blood vessels and often involves the central nervous system (CNS), making early diagnosis challenging due to non-specific symptoms.
- A study analyzed data from 17 patients, finding that most experienced sudden neurological episodes, rapid cognitive decline, and unique MRI characteristics, alongside other clinical signs such as elevated LDH levels.
- The research identified key features, or "red flags," that could aid in quicker diagnosis of CNS-involving intravascular lymphoma, emphasizing the importance of recognizing these indicators.
Article Synopsis
- Vitreoretinal lymphoma (VRL) has a poor prognosis due to high relapse rates in the central nervous system, requiring treatments like high-dose chemotherapy with autologous stem cell transplantation (HCT-ASCT).
- A study analyzed 38 adult patients treated with HCT-ASCT for isolated VRL over 11 years, showing that 84% received a thiotepa-based regimen, with some patients experiencing serious side effects.
- Results revealed a significant relapse rate, particularly in the brain, but the strategy showed relatively good median survival rates: 96 months for progression-free survival and 92 months overall.
Article Synopsis
- CAR T-cell therapy has shown promise as a treatment for central nervous system (CNS) lymphomas, despite previous concerns about neurotoxicity.
- Recent studies report high response rates in patients with CNS lymphomas, with complete response rates between 32% and 67%, and one-year progression-free survival (PFS) of 40% to 60%.
- Although neurotoxicity affects a significant percentage of patients (36% to 68%), the levels of severe neurotoxicity are relatively low (4.5% to 29%), indicating that CAR T-cell therapy could be a viable option for CNS lymphomas moving forward.